CLINICAL-SIGNIFICANCE OF THE TRIMETHADIONE TOLERANCE-TEST IN CHRONIC HEPATITIS - A USEFUL INDICATOR OF HEPATIC DRUG-METABOLIZING CAPACITY

被引：13

作者：

ABEI, M

TANAKA, E

TANAKA, N

MATSUZAKI, Y

IKEGAMI, T

ISHIKAWA, A

OSUGA, T

机构：

[1] Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305

[2] Department of Forensic Science, Institute of Community Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305

[3] Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305

来源：

JOURNAL OF GASTROENTEROLOGY | 1995年 / 30卷 / 04期

关键词：

TRIMETHADIONE; HEPATIC DRUG METABOLISM; LIVER FUNCTION TESTS; CHRONIC LIVER DISEASE; CHRONIC HEPATITIS;

D O I：

10.1007/BF02347564

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Trimethadione (TMO) was chosen as an indicator of quantitative hepatic microsomal function, and its pharmacokinetics were studied in 52 patients with chronic hepatitis. Findings in these patients were compared with those for 26 healthy subjects and 13 patients with renal failure. Patients with chronic hepatitis, but not those with renal failure, showed significant reduction in clearance (CL) and prolongation of half-life (t1/2), and the extent of abnormalities was found to reflect the severity of histologic changes in liver tissue. The serum dimethadione (DMO)/TMO ratio 4 h after the administration of TMO altered in parallel with the CL and t(1/2) of TMO, and abnormalities in this simple ratio were also related to the histologic severity of changes in the liver tissue. A low DMO/TMO ratio (<0.4) was associated with advanced histologic changes (chronic active hepatitis with bridging or chronic active hepatitis with cirrhosis), whereas a high DMO/TMO ratio (>0.4) was associated with mild histologic changes (chronic persistent hepatitis or chronic active hepatitis) (sensitivity, 0.81; specificity, 0.86). These results indicate that the DMO/TMO ratio, which can be obtained from a single blood sampling, reflects the histologic severity of changes in tissue liver, and that the TMO tolerance test is a useful indicator of quantitative liver function.

引用

页码：478 / 484

页数：7

共 34 条

[1]

Barstrow L., Small R.E., Liver function by drug metabolism, Pharmacotherapy, 10, pp. 280-288, (1990)

[2]

Bircher J., Quantitative assessment of deranged hepatic function: A missed opportunity?, Semin Liver Dis, 3, pp. 275-284, (1983)

[3]

Branch R., Drug as indicator of hepatic function, Hepatology, 2, pp. 97-105, (1982)

[4]

Branch R.A., Herbert C.M., Read A.E., Determinants of serum antipyrine half-life in patients with liver disease, Gut, 14, pp. 569-573, (1973)

[5]

Farrell G.C., Cooksley G.E., Hart P., Et al., Drug metabolism in liver disease, Gastroenterology, 75, pp. 580-588, (1978)

[6]

Willia S., Farrell G.C., Serial antipyrine clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity, Hepatology, 10, pp. 192-197, (1989)

[7]

Hepner G.W., Vessell E.S., Quantitative assessment of hepatic function by breath analysis after oral administration of14C-aminopyrine, Ann Intern Med, 83, pp. 632-638, (1975)

[8]

Monroe P.S., Baker A.L., Schneider J.E., Et al., The aminopyrine breath test and serum bile acids reflect histological severity in chronic hepatitis, Hepatology, 3, pp. 317-322, (1982)

[9]

Pauwels S., Geubel A.P., Dive C., Et al., Breath14CO2 after intravenous administration of [14C]aminopyrine in liver diseases, Dig Dis Sci, 27, pp. 49-56, (1982)

[10]

Renner E., Wietholtz H., Huguenin P., Et al., Caffeine: A model compound for measuring liver function, Hepatology, 4, pp. 38-46, (1984)

← 1 2 3 4 →